This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción G5B
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Competidores de Global Blood Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.40 |
| 52 Week High | US$70.48 |
| 52 Week Low | US$20.83 |
| Beta | 0.46 |
| 1 Month Change | 2.18% |
| 3 Month Change | 110.88% |
| 1 Year Change | 212.76% |
| 3 Year Change | 62.86% |
| 5 Year Change | 144.90% |
| Change since IPO | 48.47% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| G5B | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -1.5% | 2.1% | -1.0% |
| 1Y | 212.8% | -22.2% | 2.0% |
Rentabilidad vs. Industria: G5B exceeded the German Biotechs industry which returned -9.2% over the past year.
Rentabilidad vs. Mercado: G5B exceeded the German Market which returned -24.5% over the past year.
Volatilidad de los precios
| G5B volatility | |
|---|---|
| G5B Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: G5B's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: G5B's weekly volatility has increased from 12% to 17% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Resumen de fundamentos de Global Blood Therapeutics, Inc.
| Estadísticas fundamentales de G5B | |
|---|---|
| Capitalización bursátil | €4.69b |
| Beneficios(TTM) | -€327.07m |
| Ingresos (TTM) | €238.22m |
19.7x
Ratio precio-ventas (PS)-14.3x
Ratio precio-beneficio (PE)¿Está G5B sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de G5B | |
|---|---|
| Ingresos | US$234.86m |
| Coste de los ingresos | US$4.45m |
| Beneficio bruto | US$230.41m |
| Otros gastos | US$552.87m |
| Beneficios | -US$322.46m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.78 |
| Margen bruto | 98.10% |
| Margen de beneficio neto | -137.30% |
| Ratio deuda/patrimonio | 491.7% |
¿Cómo se ha desempeñado G5B a largo plazo?
Ver rendimiento histórico y comparativa